Viral vectors, such as adeno-associated viruses (AAV) and lentiviral viruses (LVV), are recently at the forefront of biotherapeutic development for the support of cell and gene therapies. As with ...
This study investigates how the HIV inhibitor lenacapavir influences capsid mechanics and interactions with the nuclear pore complex. It provides important insights into how drug-induced ...
This is a preview. Log in through your library . Abstract Background. Naturally occurring variants of human papillomavirus (HPV) 58 have been defined as lineages and sublineages but little is known ...
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...
(b. 1970) B.S., 1992, Lomonosov Moscow State University (Moscow, Russia); Ph.D., 1997, Columbia University; Postdoctoral Scientist 1997 – 1999, Columbia University ...
Once perceived as mere pathogens, adenoviruses have transformed remarkably, becoming indispensable allies in the fight against genetic disorders. In an era where medical innovation is paramount, ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for ...
On Wednesday, the Nobel Committee announced that it had awarded the Nobel Prize in chemistry to researchers who pioneered major breakthroughs in computational chemistry. These include two researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback